May 24, 2023 4:05 pm EDT Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
May 2, 2023 8:30 am EDT Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
Apr 25, 2023 8:00 am EDT Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
Mar 30, 2023 8:00 am EDT Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
Mar 23, 2023 8:00 am EDT Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
Feb 13, 2023 8:00 am EST Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
Jan 25, 2023 4:01 pm EST Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA